Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications.
about
Is there a fatty acid taste?Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsHeart-Type Fatty Acid Binding Protein Level as a Tool in Identification of Early Cardiac Effects of Diabetic Ketoacidosis.Point-of-care test of heart-type fatty acid-binding protein for the diagnosis of early acute myocardial infarction.Preoperative serum h-FABP concentration is associated with postoperative incidence of acute kidney injury in patients undergoing cardiac surgery.Heart-type fatty acid binding protein is an independent predictor of death and ventricular dysfunction after coronary artery bypass graft surgery.Lysophosphatidylcholines activate G2A inducing G(αi)₋₁-/G(αq/)₁₁- Ca²(+) flux, G(βγ)-Hck activation and clathrin/β-arrestin-1/GRK6 recruitment in PMNs.Utility of Heart-type Fatty Acid Binding Protein as a New Biochemical Marker for the Early Diagnosis of Acute Coronary SyndromeDiagnosis of Non-ST-Elevation Acute Coronary Syndrome by the Measurement of Heart-Type Fatty Acid Binding Protein in Serum: A Prospective Case Control StudyIschemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I.Evidence for Acute Myocardial and Skeletal Muscle Injury after Serial Transthoracic Shocks in Healthy Swine.Heart type fatty acid binding protein response and subsequent development of atherosclerosis in insulin resistant polycystic ovary syndrome patients.A proteomic view of isoproterenol induced cardiac hypertrophy: prohibitin identified as a potential biomarker in rats.Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction.Perioperative heart-type fatty acid binding protein levels in atrial fibrillation after cardiac surgery.Inosine and hypoxanthine as novel biomarkers for cardiac ischemia: from bench to point-of-careFree fatty acids as a cardiovascular risk factor.Oral thresholds and suprathreshold intensity ratings for free fatty acids on 3 tongue sites in humans: implications for transduction mechanismsPlasma free Fatty Acid concentrations as a marker for acute myocardial infarction.Biomarkers of vulnerable plaque: the missing link with ischemia.Gender-specific differences in biomarkers responses to acute coronary syndromes and revascularization procedures.Review on cardiovascular risk prediction.The Pancreatic β-Cell: A Bioenergetic Perspective.Key Questions for Translation of FFA Receptors: From Pharmacology to Medicines.Increases in serum concentration of human heart-type fatty acid-binding protein following elective coronary intervention.LysoPCs induce Hck- and PKCδ-mediated activation of PKCγ causing p47phox phosphorylation and membrane translocation in neutrophils.High peripheral levels of h-FABP are associated with poor prognosis in end-stage heart failure patients with mechanical circulatory support.A proteomic study of the effects of ramipril on post-infarction left ventricular remodelling in the rabbit.Vasculo-protective effect of BMS-309403 is independent of its specific inhibition of fatty acid-binding protein 4.
P2860
Q22337035-BE23109A-8243-4DE5-995C-C1FA24F51D01Q27007849-46E0502B-EF34-4D88-A061-A953D89764DBQ33776020-69B1DA41-83D9-4DFE-95A0-D1FFC504BE09Q34097486-FF3AD5C8-4F84-46FE-8EB3-D01FFD3E5B58Q34217320-86028D8E-49A4-4F86-94EF-F8E508BEA750Q34425241-49382454-9AAF-4EC3-BC25-42A345ED818EQ35090466-75B96B58-327C-4975-9404-80F038668E12Q35139560-40486CFC-5BE9-4451-95E7-792D5A0AB61FQ35623487-DD2F94F0-6404-4C7E-997B-0C6FBA9C52F2Q35662925-F4C296F5-CE5D-4679-BD5D-829BB642A865Q36127849-0A9C8807-D97C-4AB5-A209-A136BD6CD35CQ36614485-C47B5097-F9A6-4791-BBED-E6B6FF7BFFC6Q36885466-FDBBE87B-FF59-4EFF-AD5E-432C2817C1A7Q36931261-BD5A7351-7466-4F8B-B93B-36A2B07DD5EEQ36943516-646656FB-F9D9-4052-B504-0429B506D0D9Q37071026-20DDCBAC-9FA1-4947-B9F3-BA6502FD205EQ37208848-CAC108A2-FE57-4D43-AFFC-2417BEBEC306Q37288808-BDEF8CF3-29C8-4AF6-BBD3-76B7C772B1C0Q37429551-197EF2B9-CD58-4213-B7CE-3704277630FFQ37765286-BB938C1E-EABB-42B4-8910-47F5E31C9DF9Q37919535-32880A33-C055-42D5-B50C-09BD37197BEEQ38373055-CF71B07A-7F67-42F8-95E0-5A78C2B7D792Q38943061-8011A8CB-5CAA-4F7B-B2F1-3D5014ADFE94Q39016250-DF1A0CA8-DA60-42AF-B25B-723DD23B00B3Q39968283-95058D79-9C92-49CF-8D63-A36DE0E2C9D3Q40398087-606FCE32-D880-4B2C-97A0-B180CD0DF773Q45907477-B676B450-329B-423B-A36A-C7AF669EBA98Q46516544-155BB763-FCB9-4776-BC36-779F17439107Q50730906-98CDFDE4-0A19-4C8F-8348-A4E64AC7622E
P2860
Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Unbound free fatty acids and h ...... ays and clinical applications.
@ast
Unbound free fatty acids and h ...... ays and clinical applications.
@en
Unbound free fatty acids and h ...... ays and clinical applications.
@nl
type
label
Unbound free fatty acids and h ...... ays and clinical applications.
@ast
Unbound free fatty acids and h ...... ays and clinical applications.
@en
Unbound free fatty acids and h ...... ays and clinical applications.
@nl
prefLabel
Unbound free fatty acids and h ...... ays and clinical applications.
@ast
Unbound free fatty acids and h ...... ays and clinical applications.
@en
Unbound free fatty acids and h ...... ays and clinical applications.
@nl
P2093
P1433
P1476
Unbound free fatty acids and h ...... ays and clinical applications.
@en
P2093
Hassan M E Azzazy
Maurice M A L Pelsers
Robert H Christenson
P356
10.1373/CLINCHEM.2005.056143
P407
P577
2005-11-03T00:00:00Z